GlassScriptPhysician profile
Audra J Braun
NPI 1942449608
$1,222.88
in general payments reported to CMS, 2019-2025
17 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2024: $553 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138 · Education: $84.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.38 |
| Education | $84.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $391.20 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Merck Sharp & Dohme LLC | $198.55 | 2023-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $103.20 | 2024-2025 | Opdivo |
| Daiichi Sankyo INC. | $99.94 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Aveo Pharmaceuticals, INC. | $84.50 | 2024 | |
| Glaxosmithkline, LLC. | $58.47 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $50.18 | 2025 | Padcev, Xtandi |
| Pfizer INC. | $39.54 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $34.26 | 2024 | Calquence |
| Incyte Corporation | $23.64 | 2024 | Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $23.38 | 2025 | |
| Pharmaessentia USA Corporation | $22.04 | 2025 | Besremi |
| Stemline Therapeutics INC. | $21.82 | 2025 | Orserdu |
| Genentech USA, INC. | $21.51 | 2025 | Tecentriq Hybreza, Tecentriq, Alecensa |
| Genmab U.S., INC. | $19.64 | 2025 | Epkinly |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $16.96 | 2024 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $14.05 | 2024 | Ninlaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.